ODAC Asks Sandoz If Biosimilar Price Is Right
Oncologic Drugs Advisory Committee member wants to know if approval of filgrastim would lead to lower prices; Sandoz responds that price may be at parity, but cost to patients and payers would be lower.
Oncologic Drugs Advisory Committee member wants to know if approval of filgrastim would lead to lower prices; Sandoz responds that price may be at parity, but cost to patients and payers would be lower.